Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E et al. Blood Cancer J. 2016 May 27;6:e428. doi: 10.1038/bcj.2016.37.

Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis.
Bhatti S et al. Eur Heart J Cardiovasc Imaging. 2016 May 25. pii: jew101. [Epub ahead of print].

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
Ryu D et al. Oncotarget. 2016 May 19. doi: 10.18632/oncotarget.9478. [Epub ahead of print].

Circulating aberrant plasma cells allows risk stratification of patients with myeloma.
Periago A et al. Am J Hematol. 2016 May 24. doi: 10.1002/ajh.24431. [Epub ahead of print].

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.
Majithia N et al. Leukemia. 2016 May 23. doi: 10.1038/leu.2016.147. [Epub ahead of print].

Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM et al. Ann Hematol. 2016 May 16. [Epub ahead of print].

Could renal impairment be a positive predictor of outcome in autografts for myeloma?
Szer J et al. Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.138. [Epub ahead of print].

Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y et al. Medicine (Baltimore). 2016 May;95(19):e3521. doi: 10.1097/MD.0000000000003521.

Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.
Abbi KK et al. Br J Haematol. 2016 May 12. doi: 10.1111/bjh.14081. [Epub ahead of print].

MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings.
Dutoit JC et al. Insights Imaging. 2016 May 10. [Epub ahead of print].

The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.
Dotterweich J et al. PLoS One. 2016 May 9;11(5):e0155087. doi: 10.1371/journal.pone.0155087. eCollection 2016.

Genome-wide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Mikulasova A et al. Eur J Haematol. 2016 May 9. doi: 10.1111/ejh.12774. [Epub ahead of print].

Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K et al. Hematol Oncol. 2016 May 3. doi: 10.1002/hon.2300. [Epub ahead of print].

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomaticmultiple myeloma.
González-Calle V et al. Leukemia. 2016 May 27. doi: 10.1038/leu.2016.123. [Epub ahead of print].